

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

VOLUNTARY ANNOUNCEMENT UPDATED INFORMATION OF THE GROUP'S PRODUCTS

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors of the Company is pleased to announce that, Zhuhai United Laboratories Co., Ltd. (珠海聯邦制藥股份有限公司), a wholly-owned subsidiary of the Company, has received the notices of acceptance of application for production in relation to insulin aspart, insulin aspart injection (specification: 3ml: 300 units (refilled pen-type)), insulin aspart injection (specification: 3ml: 300 units (disposable pen-type)), insulin aspart 30 injection (specification: 3ml: 300 units (refilled pen-type)) and insulin aspart 30 injection (specification: 3ml: 300 units (disposable pen-type)) of the Group from Guangdong Food and Drug Administration during the period from 10 November 2017 to 13 November 2017, with acceptance numbers of CXSS1700027 粵, CXSS1700028 粵, CXSS1700029 粵, CXSS1700030 粵 and CXSS1700031 粵 respectively.

Insulin aspart is a short-acting insulin analogue characterized by fast onset of action and high safety, which can better control the blood glucose level after meal. Currently, the Group is the pharmaceutical enterprise which owns both the second and third generation insulin products in China. The application for the production of insulin aspart will further optimize the insulin product offerings of the Group.

The Company will be devoted to the development of its insulin series, which is expected to create more values for the Company and its shareholders.

On behalf of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 15 November 2017

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.